Carmustine as a Supplementary Therapeutic Option for Glioblastoma: A Systematic Review and Meta-Analysis

Background: Glioblastoma (GBM) is the most aggressive type of primary malignant brain tumor. Carmustine is used by intravenous injection or local implantation in the resection cavity for gliomas, including GBMs. However, the therapeutic potential of carmustine is not well-recognized. This analysis a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Zhi-Ze, Wang, Ze-Fen, Lan, Tian, Huang, Wen-Hong, Zhao, Yu-Hang, Ma, Chao, Li, Zhi-Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527463/
https://www.ncbi.nlm.nih.gov/pubmed/33041980
http://dx.doi.org/10.3389/fneur.2020.01036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527463/
https://www.ncbi.nlm.nih.gov/pubmed/33041980
http://dx.doi.org/10.3389/fneur.2020.01036

Ejemplares similares